thonzylamine has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
thonzylamine: major descriptor (72-84); file-maintained to PYRIMIDINES
Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, K | 1 |
| Kanetaka, K | 1 |
| Yoneda, A | 1 |
| Kobayashi, S | 1 |
| Maruya, Y | 1 |
| Isagawa, Y | 1 |
| Yoshimoto, T | 1 |
| Migita, K | 1 |
| Kawaguchi, Y | 1 |
| Kuba, S | 1 |
| Morita, M | 1 |
| Okada, S | 1 |
| Kosaka, T | 1 |
| Yamaguchi, S | 1 |
| Inoue, Y | 1 |
| Adachi, T | 1 |
| Hidaka, M | 1 |
| Torashima, Y | 1 |
| Ito, S | 1 |
| Takatsuki, M | 1 |
| Eguchi, S | 1 |
1 other study available for thonzylamine and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D | 2021 |